Trial Profile

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retatrutide (Primary) ; Dulaglutide
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

02 Sep 2024 Results assessing the effects of retatrutide on circulating ANGPTL3/8 complex concentrations, presented at the ESC Congress 2024 - Annual Congress of the European Society of Cardiology
06 Oct 2023 Results assessing efficacy and safety of RETA vs placebo (PBO) in people with T2D presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
26 Jun 2023 Results presented in an Eli Lilly Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com